The effects of anaglipitin, a DPP-4 inhibitor, on blood lipids in type 2 diabetic patients.

Not Applicable

• Conditions: Type 2 Diabetes Mellitus

• Registration Number: JPRN-UMIN000014531
• Lead Sponsor: Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine

Brief Summary

Treatment with anagliptin for 24 weeks significantly reduced fasting serum apolipoprotein (Apo) B-48 compared with the control group (P < 0.05).

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-07-11
• Study Completion: 2018-06-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

Not provided

Exclusion Criteria

Type 1 diabetes Treatment with insulin, glinides, high doses of SU Patients with repetitive or unaware severe hypoglycemia Severe liver diseases Patients with hemodialysis Severe cardiac diseases or acute myocardial infarction within 6 months Severe anemia Severe pancreatitis Malignant diseases Uncontrolled endocrine diseases Severe infections or surgical treatment Severe diabetic complications Severe bowel diseases Alcohol addiction Pregnant or possibly pregnant women History of allergic reaction to DPP4 inhibitors Patients who a physician-in-charge considers is unsuitable for the trial.

Study & Design

• Study Type: Interventional
• Study Design: Not specified